OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is...
May 22, 2025, 7:36 AM EDT - 6 weeks ago
May 2, 2025, 7:30 AM EDT - 2 months ago
Apr 9, 2025, 7:54 AM EDT - 3 months ago
Apr 3, 2025, 7:30 AM EDT - 3 months ago
Mar 26, 2025, 7:16 AM EDT - 3 months ago
Mar 25, 2025, 7:00 AM EDT - 3 months ago
Feb 14, 2025, 6:10 PM EST - 5 months ago